Ulrich Neumann, MSc MA BSc BA, serves as Senior Director of Certara in New York, where he leads the company’s US Access and Commercial Strategy team. He is also the Founder of Pharmvivo Ventures, a NYC-based strategic knowledge and networking platform for b2b exchanges in life sciences. With a dual background in business and public administration, Ulrich consults on reimbursement, patient access and launch strategy, as well as developments on the US legislative, policy and managed markets landscape. He also leads commercial due diligence projects at the intersection of health technology/ pharma.
Ulrich’s business experience lies in defining product strategy, value messaging and b2b brand development. The founder of several entrepreneurial ventures, He has advised clients on go-to-market projects for 12+ years, leading multi-million $ P&Ls and cross-functional academic/commercial teams in Europe and the US. He is the author of two books in the policy field and has published various trade articles, whitepapers, reports and posters on critical managed care topics such as adherence, reimbursement of infused vs. oral oncolytics, formulary placement, evidence frameworks, payment reform, innovative contracting or manufacturer IDN collaborations. A frequent expert contributor and conference speaker, Ulrich manages and hosts “The Market Access Radar”, a bi-weekly broadcast on current pharma policy and reimbursement topics.
Ulrich holds an MSc from the London School of Economics, an MA (Marketing, Strategy) from University of Southern California, Annenberg School and Marshall School of Business. He’s currently affiliated with London’s Imperial College for Medicines, Science and Technology, and recently been invited to give a graduate seminar on clinical trial innovation at Rutgers University Business School (Irvine Center). An active member of AMCP, AMBA and ISPOR, he is also a nominated Fellow of the Royal Society of Arts and Commerce since 2014.